G1 INDUCES ENDOTHELIUM-DEPENDENT VASORELAXATION THROUGH ACTIVATION OF EPIDERMAL GROWTH FACTOR RECEPTOR


Eun Jin Jang, Jeffrey B. Arterburn and In Kyeom Kim

Department of Pharmacology, Kyungpook National University School of Medicine, 101 Dongin-2-Ga, Daegu 700-422 Republic of Korea

Abstract:

Objectives: The G-protein-coupled-receptor 30 (GPR30) agonist G1 induces endothelium-dependent relaxation. We tested the hypothesis that G1 induces endothelium-dependent vasorelaxation through activation of epidermal growth factor (EGF) receptor.

Methods:
Rat aortic rings were mounted in organ baths, and subjected to relaxation upon contraction.

Key findings:
G1 induced endothelium-dependent vasorelaxation, which was attenuated by pretreatment with either L-Nω-nitroarginine methyl ester (L-NAME), an inhibitor of nitric oxide synthase, or G15, a GPR30 antagonist. Neither a general estrogen receptor antagonist ICI 182,780 nor a selective estrogen receptor-α antagonist methyl-piperidino-pyrazole dihydrochloride (MPP) affected G1-induced vasorelaxation. However, pretreatment with EGF receptor blockers AG1478 or DAPH attenuated G1-induced vasorelaxation. In addition, pretreatment with Akt Inhibitor VIII, but not with a PI3K inhibitor LY294002, attenuated vascular relaxation induced by cumulative addition of G1.

Conclusions:
G1 induces endothelium-dependent vasorelaxation through activation of EGF receptor and Akt pathway in rat aorta.

Keywords:
G1, GPR30, EGF receptor, PI3K/Akt kinase and endothelium-dependent vasorelaxation.

ABBREVIATION:


G1                   =    (±)-1-[(3aR*,4S*,9bS*)-4-(6-Bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]- ethanone
GPR30            =    G-protein-coupled-receptor 30
EGF receptor   =    epidermal growth factor receptor
PI3K                =    phosphatidylinositol-3 kinase